Abstract
During the past few years, we have systematically published the short-term and the intermediate analysis of prospective randomized studies [4, 6, 15] with adjuvant combination chemotherapy in operable breast cancer having histologically positive axillary lymph nodes (N+). More recently, the 5-year results of the first trial were reported [11] as well as a retrospective analysis on the dose-response effect of adjuvant chemotherapy [2].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bonadonna G, Rossi A, Valagussa P, Banfi A, Veronesi U (1977) The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance. Cancer 39:2904–2915
Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10–15
Bonadonna G, Valagussa P, De Palo G (1981) The results of adjuvant chemotherapy in breast cancer are predominantly due to the hormonal change such therapy induces: The view against. In: Van Scoy-Mosher MB (ed) Controversies in medical oncology. G. K. Hall & Co., Boston (in press)
Bonadonna G, Valagussa P, Rossi A et al. (1978) Are surgical adjuvant trial altering the course of breast cancer? Semin Oncol 5:450—464
Bonadonna G, Valagussa P, Tancini G, Di Fronzo G (1980) Estrogen-receptor status and response to chemotherapy in early and advanced breast cancer. Cancer Chemother Pharmacol 4: 37–41
Brambilla C, Valagussa P, Bonadonna G, Veronesi U (1980) Sequential adjuvant chemotherapy in postmenopausal (≤ 65 year) breast cancer. Proc Am Assoc Cancer Res 21: 189
Habs M, Schmahl D (1981) Carcinogenic activity of cyclophosphamide, methotrexate, 5-fluorouracil treatment in rats. Int J Cancer (in press)
Legha SS, Buzdar AU, Smith TL et al. (1979) Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med 91:847–852
Lippman ME, Allegra JC, Thompson EB et al. (1978) The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223–1228
Norton L, Simon R (1977) Tumor size, sensitivity to therapy and design of treatment schedules. Cancer Treat Rep 61:1307–1317
Rossi A, Bonadonna G, Valagussa P, Veronesi U (1981) Multimodal treatment in operable breast cancer: 5-year results of the CMF program. Br Med J (in press)
Skipper HE (1980) Response of advanced breast cancer to CMF (cyclophosphamide, methotrexate, 5-fluorouracil). Birmingham, Ala., Southern Research Institute (Booklet 2)
Skipper HE (1980) Breast cancer treated by means of mastectomy and mastectomy followed by 12 or 6 cycles of CMF. Birmingham, Ala., Southern Research Institute (Booklet 4)
Steroid Receptors in Breast Cancer. An NIH Consensus Development Conference (1980) Bethesda, Maryland, June 27–29, 1979. Cancer 46:2759–2963
Tancini G, Bajetta E, Marchini S, Valagussa P, Bonadonna G, Veronesi U (1979) Preliminary 3-year results of 12 versus 6 cycles of surgical adjuvant CMF in premenopausal breast cancer. Cancer Clin Trials 2:285–292
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Bonadonna, G. et al. (1982). Multimodal Therapy with CMF in Resectable Breast Cancer with Positive Axillary Nodes: The Milan Institute Experience. In: Mathé, G., Bonadonna, G., Salmon, S. (eds) Adjuvant Therapies of Cancer. Recent Results in Cancer Research, vol 80. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81685-7_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-81685-7_25
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81687-1
Online ISBN: 978-3-642-81685-7
eBook Packages: Springer Book Archive